Physician profile
Robert Tokarek
NPI 1083619407
$157,688.20
in general payments reported to CMS, 2019-2025
39 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $18K · 2021: $12K · 2022: $30K · 2023: $21K · 2024: $15K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $11K · Travel and Lodging: $2,285 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,125.00 |
| Food and Beverage | $11,184.23 |
| Travel and Lodging | $2,284.57 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $86,360.70 | 2019-2022 | |
| Janssen Biotech, INC. | $41,402.00 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $8,532.67 | 2019-2025 | |
| Galderma Laboratories, L.P. | $7,324.44 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $2,604.47 | 2019-2024 | Otezla |
| Abbvie INC. | $2,373.05 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,186.78 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $1,024.53 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $912.82 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $850.47 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $831.17 | 2019-2025 | |
| Incyte Corporation | $701.79 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $612.87 | 2022-2025 | Sotyktu |
| Pfizer INC. | $482.10 | 2023-2025 | |
| Leo Pharma INC. | $451.35 | 2020-2025 | Adbry |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tokarek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.